The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Evolving treatment strategies for early-stage lung cancer with immunotherapy
Samreen Ahmed, FRCP, MD, MBBS, MSc, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the evolving treatment landscape for early-stage lung cancer. With systemic therapies now playing a key role, treatment approaches include adjuvant, peri-operative, and neoadjuvant options, often combined with immunotherapy. Several clinical trials, including the Phase III CheckMate 816 (NCT02998528) and KEYNOTE-671 (NCT03425643) trials, have demonstrated overall survival benefits, highlighting the potential of immunotherapy to reduce recurrence and improve long-term outcomes. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
